Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04599634
Title Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

follicular lymphoma

marginal zone B-cell lymphoma

mantle cell lymphoma

chronic lymphocytic leukemia

B-cell lymphoma

Therapies

Hu5F9-G4 + Obinutuzumab + Venetoclax

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.